Hormone Replacement Therapy Market

Global Hormone Replacement Therapy Market Size (2022 to 2027)

The global hormone replacement therapy market was worth USD 16.89 billion in 2022 and will grow to USD 23.92 billion by 2027, showcasing a CAGR of 7.21% during the forecast period.

Hormonal replacement therapy is a medical term used to substitute the natural hormones in the human body with other hormones. Hormone replacement therapy (HRT) is the latest technological roadmap that targets hormonal imbalance in people. This process involves stimulating or induction hormones like estrogen, thyroid-stimulating hormone (TSH), testosterone, etc.

MARKET DRIVERS:

The rising geriatric population and behavioral changes are majorly driving the growth of the global hormone replacement therapy market.

As People age, their health concerns increase, resulting in chronic illness in the population. Hormonal balance is necessary for reducing the Impact of many diseases. In the case of lactating women, hormones like progesterone and estrogen play a vital role due to the behavioral changes in women's lifestyles; there is a massive demand for hormone therapy in pre and post-pregnancy and lactating periods, respectively. Apart from these aspects, increased expenditure on R&D and people's consciousness of health are also the aspects that are driving the global hormone replacement therapy market for further expansion. There are many opportunities for the HRT process; due to the people's behavioral aspects, there is a lot of scope for global hormone replacement therapy market expansion. Many Non- curable diseases are nowadays addressed with Hormone therapy techniques. Particularly in the case of women experiencing menopause in the very early stage, like in the mid-40s, they are interested in exploring the H.R. therapies for estrogen and progesterone therapies. In addition, impotent males and people who have medical illnesses are tilting towards these kinds of safe hormone replacement therapies. Increased investments in developing countries for such advanced therapies provide a significant opportunity for the market players to expand and capture the segment in those countries.

MARKET RESTRAINTS:

The high cost of these therapies, some side effects, and product shortages due to weak pipelines are some factors that hinder the growth of the global hormone replacement therapy market. Generally, harmonic imbalances are pretty natural in people who do not maintain a proper lifestyle, so correcting those imbalances is a tedious task and requires a lot of effort, both behaviorally and financially. So, it is a barrier for the market. Regulatory approvals for these therapies are complex and cannot be obtained easily. As these therapies are highly advanced, less developed countries lack awareness and cannot afford to invest in these kinds of research. Less penetration and a lack of prominent players in significant markets like APAC are barriers to expanding the global hormone replacement therapy market. In Hormone replacement therapies process is involved where there is a disease that is involved with hormonal imbalance. The therapy targets particular cells, as the adjoining cells should not be disturbed. So this makes Hormone replacement therapy costlier. Also, HRTs make patients more exposed to cancer and cell disorders risks. Apart from all the above-stated factors getting regulatory approvals for the HRTs, either for clinical research or application, is quite challenging.

COVID-19 Impact on the global Hormone replacement therapy market:

The COVID-19 pandemic initially disrupted the market due to supply chain and demand-side disruptions. But the players in the market had opened up the market to new avenues. There is ongoing research to apply the HRTs in treating the covid 19 infected patients. Some findings show that post-menopausal women's recovery and survival rates are high. So, scientists are relating the effect of estrogen in inhibiting the virulence caused by the covid 19. There are also ongoing clinical trials to infuse estradiol to increase the immunity in women patients to reduce the infection caused by covid 19. Estradiol and many other hormone replacement therapies are being researched clinically to cure the covid 19 infected patients.

REPORT COVERAGE:

This research report on the global hormone replacement therapy market has been segmented and sub-segmented into the following categories

Hormone Replacement Therapy Market - By Type:

• Estrogenic Replacement Therapy
• Growth Hormone Replacement Therapy
• Thyroid Replacement Therapy

Based on Type, the estrogenic replacement therapy segment dominates the market with a market share of more than 60%. Estrogenic replacement therapy accounts for more than 50% of the share market. This replacement therapy in which estrogenic hormones are commonly used to treat the symptoms seen in women for menopause. This helps to decrease short-term changes of menopause, like vaginal dryness, hot flashes, and disturbed sleep in women.

Thyroid replacement therapy is the next segment that drives the market forward. This therapy is used to level the thyroid hormones in the body. This is mainly used for the treatment of hypothyroidism. A large portion of this therapy is taken in India and America. Forty percent of women in the U.S. suffer from thyroid problems, which drives the market forward.

Hormone Replacement Therapy Market - By Route of Administration:

• Oral
• Parenteral
• Transdermal
• Other Routes

Based on the administration route, the administration segment's oral route is regarded as one of the safest and most preferred routes of drug administration. Therefore, the Oral Route of Administration segment is accounted for the highest share market. This oral segment is a sub-division of enteral administration.

Transdermal is the next segment that drives the market forward. In this, the drug or medicine is given through the skin for more absorption of the drug into the bloodstream, giving a faster response than oral. But most doctors not preferred this treatment for every thyroid patient.

Hormone Replacement Therapy Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Geographically, the North American Region is likely to dominate the global market during the forecast period due to the factors such as new methods or products in drug delivery systems, the development of new drugs, and an increase in the target population. Also, the growing incidence of menopause disorders, the rising prevalence of hormone deficiency disorders, and the awareness among the people related to these therapies further drive the North American regional market. More than 50 million American women use estrogen replacement therapy (ERT) for chronic disease prevention. Health Canada has approved hormone replacement products to treat menopausal symptoms such as night sweats and vaginal dryness. This Region also provides pills, patches, and gel for these diseases. In addition, the U.S. National Institutes of Health (NIH) launched the Women's Health Initiative to study and research post-menopausal women in 40 U.S. centers.

The Asia-Pacific market is likely to register the highest growth rate over the forecast period due to the factors such as awareness among people regarding hormone replacement therapy in APAC countries such as China, India, and Japan. Pediatric growth hormone deficiency is a rare disease caused due to insufficient secretion of growth hormone from the pituitary gland. A decrease in hormone growth can lead to different types of psychological disorders. In China, nearly 3.4 million children with growth hormone deficiency drive the market growth. In 2021, Hypoparathyroidism was the first hormone replacement therapy in China. Hormonal replacement therapy has been increasing in Japan in recent years. The Japan Society of Obstetrics and Gynecology and the Japan Society for Menopause and Women's Health formed the hormone replacement therapy rules. Most Indian women are facing menopause problems. It is a natural phenomenon where the menstrual cycle ceases at around 45-50 years in India, requiring hormone replacement therapy.

The Middle East and Africa are likely to have moderate demand due to increasing occurrences of chronic diseases like cancer that require hormone replacement therapy. Due to the increase in healthcare advancements and government initiatives supporting the growth of the hormone replacement therapy market in the Middle East and Africa region. Countries such as Saudi Arabia, Qatar, and others also drive the market forward. Most women in Saudi Arabia are suffering from menopausal symptoms and breast cancer and would like to prefer hormone replacement therapy as an ideal method to treat menopausal symptoms. Hormone therapy is also used for treating breast cancers.

Latin America also has the market share due to increasing women's healthcare, increasing spending on hormone replacement therapy, and the demand for estrogen replacement drives the market forward in this Region. Mexico and Brazil share the most significant portion of this Region. In Brazil, transgender people are highly prone to gender dysphoria, requiring testosterone hormone therapy.

KEY MARKET PARTICIPANTS:

Some of the prominent companies operating in the global hormone replacement therapy market profiled in the report are Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories, Amgen, Merck & Co, Bayer, Eli Lily, Novo Nordisk, Wyeth, F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co. Inc. Leading companies are focusing on collaborations and mergers, which are anticipated over the next seven years to share the cost of technology and innovation in this area.

RECENT MARKET DEVELOPMENTS:

• In December 2019, Pfizer, Inc. introduced a new drug known as Xtandi, which has received acceptance from U.S. FDA. This Xtandi is a combination of anti-hormone therapy and helps reduce cancer spreading. Pfizer completed the Weiss merger in December 2014, outpacing popular products such as Prempro and Premarin.
• In 2021, I-Mab, a biopharmaceutical company, partnered with Jumpcan Pharmaceutical Group to develop novel biologics, Eftansomatropin alfa. It is an innovative long-acting recombinant human growth hormone (rhGH) utilized for Genexine's patented half-life extension sync fusion technology.
• In 2022, Hormone Replacement Therapy was launched by Lindora. They offer this therapy because the lack of hormone levels in the body leads to several changes, such as fatigue, anxiety, decreased libido, weight gain, and sleeplessness problems. In addition, ORLANDO, an oral testosterone replacement therapy for adult males, was launched by Halozyme in 2022. This therapy is used by people suffering from diseases due to a shortage or absence of endogenous testosterone.
• In 2022, Pfizer Inc. and OPKO Health Inc. joined and announced the approval for the next-generation long-acting recombinant human growth hormone NGENLA. This is given to people suffering from insufficient growth hormone secretion.